Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today presented preclinical data related to the company’s cyclin ...
Survival data following phase 1/2 studies using precision tumor-targeted gene delivery to advanced chemotherapy-resistant malignancies. This is an ASCO Meeting Abstract from the ASCO Breakthrough: A ...
Proxygen GmbH has disclosed molecular glue degraders comprising a cullin-ring E3 ligase (CRL) binding moiety acting as cyclin-dependent kinase 12 (CDK12)/cyclin K degradation inducers. They are ...
SAN FRANCISCO--(BUSINESS WIRE)--Circle Pharma, in collaboration with the laboratory of Violeta Serra, Ph.D., at Vall d’Hebron Institute of Oncology (VHIO) in Barcelona, Spain, recently unveiled ...
SAN FRANCISCO--(BUSINESS WIRE)--Circle Pharma announced today that two poster presentations at the American Association for Cancer Research (AACR) Annual Meeting held April 14-19, in Orlando, Florida, ...
New platform for collecting real-world data on directing clinical trial optimization, especially for rare mutations in lung cancer. This is an ASCO Meeting Abstract from the ASCO Breakthrough: A ...
A 'pocket' on the protein cyclin B is responsible for ensuring that the steps of cell division take place in the correct order. Cell division is key for life. Every organism -- from the smallest yeast ...
(RTTNews) - Zentalis Pharmaceuticals Inc. (ZNTL) Thursday announced that its lead drug candidate Azenosertib has been granted FDA's Fast Track designation for the treatment of platinum-resistant ...
Small-cell lung cancer (SCLC) and some other cancers involve dysregulation of the transcription factor E2F, and apoptosis can be induced in those cells by blocking the interaction of the RxL sequence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback